Is “MB12” a pembrolizumab biosimilar?
There is no clear, widely recognized public labeling that identifies “MB12” as a pembrolizumab biosimilar in the core reference sources typically used to track biologic products and biosimilar brands.
What is pembrolizumab, and what would make a product a “biosimilar”?
Pembrolizumab is an anti–PD-1 monoclonal antibody (brand: Keytruda). A true biosimilar to pembrolizumab would be expected to have regulatory approval as a biosimilar/biologic similar product to pembrolizumab (not just a “candidate” or “related” antibody), typically with demonstrated similarity in structure, function, and clinical performance.
Is MB12 a clinical-trial candidate rather than an approved biosimilar?
“MB12” is commonly used as a code name for investigational biologics in clinical development. If MB12 is being discussed in connection with pembrolizumab, it is more likely an investigational candidate (or internal development code) unless and until it is approved and marketed under a biosimilar name in a specific jurisdiction.
How can you verify whether MB12 is actually an approved pembrolizumab biosimilar?
To confirm, you would look for:
- A regulator-issued approval (for example, FDA, EMA, or another national regulator) that explicitly lists the product as a biosimilar to pembrolizumab.
- The marketed brand name and/or biosimilar designation tied to MB12’s development code.
- Trial registry entries that show MB12’s target (PD-1), sponsor, and whether it progressed to approval.
What to check next: if you share context, I can pin it down
If you tell me where you saw “MB12” (a news article, a trial registry link, a company name, or a country like China/EU/US), I can map it to the specific pembrolizumab biosimilar candidate or approved product and confirm what stage it is at.
Patent/exclusivity angle (only if you mean an approved biosimilar launch)
If your goal is to understand when a pembrolizumab biosimilar can launch in a specific market, DrugPatentWatch.com is a practical place to check relevant patent estates and timelines for Keytruda-related protection.
Source: DrugPatentWatch.com – Pembrolizumab (Keytruda) patents
Sources